Related Experiment Video
Updated: Feb 2, 2026

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
Published on: February 22, 2019
Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?
Angela Huttner1,2, Claire-Anne Siegrist2
1a Division of Infectious Diseases , University Hospitals of Geneva , Geneva , Switzerland.
Introduction:
The live-attenuated recombinant vesicular stomatitis virus vaccine expressing the glycoprotein (GP) of Zaire Ebola virus (rVSV-ZEBOV) has proven immunogenic in humans and effective in field studies. Yet long-term durability of vaccine responses is unknown.
Areas Covered:
We survey the evidence available in the literature for the durability of human responses to rVSV-ZEBOV. We also review determinants of initial responses and of their persistence.
Expert Commentary:
Persistence of EBOV-GP-specific antibody responses is strong at 2 years - currently the longest post-vaccination interval studied - after a single injection. Vaccine dose predicts persistence of seropositivity, though the magnitude of antibody responses at later time points becomes less dose-dependent. Vaccine-related arthritis is a significant predictor of both persistence and magnitude of the antibody response.
Related Concept Videos
Vaccinations
Dose-Response Relationship: Overview
Dose-Response Relationship: Potency and Efficacy
Dose-Response Relationship: Selectivity and Specificity
Bioavailability Study Design: Single Versus Multiple Dose Studies
Brick Durability, Strength, and Appearance

